Search Records

Briefing Materials prepared for the Minister’s appearance before the Committee on Health related to Canada’s vaccination strategy

Research: Gap analyses to assess Canadian readiness for respiratory syncytial virus vaccines: Report from an expert retreat. Published on Canada Communicable Disease Report (CCDR), volume 46-4, April 2, 2020.

The list below includes all applications received by Health Canada for drugs and vaccines used for the COVID-19 pandemic. This list includes applications received under the interim order and those received under the Food and Drug Regulations. The current status of each application is also noted.

Drugs and vaccines that have been authorized by Health Canada for use in relation to the COVID-19 pandemic are listed here.

The list below includes all applications received by Health Canada for drugs and vaccines used for the COVID-19 pandemic. This list includes applications received under the interim order and those received under the Food and Drug Regulations. The current status of each application is also noted.

Drugs and vaccines that have been authorized by Health Canada for use in relation to the COVID-19 pandemic are listed here.

This Points to Consider document lays out a regulatory approach for updating authorised coronavirus vaccines should mutations at any time make them less efficacious due to insufficient cross-reactivity.

Sponsors of COVID-19-related drug and vaccine clinical trials can choose between 2 different processes: existing process outlined in the Food and Drug Regulations or process outlined in the new interim order for clinical trials for medical devices and drugs related to COVID-19.

HESA February 26 - President of PHAC appeared with the Vice-President of Logistics and Operations

Research: Overview of the respiratory syncytial virus vaccine candidate pipeline in Canada. Published on Canada Communicable Disease Report (CCDR), volume 46-4, April 2, 2020.